MREO · Mereo BioPharma Group plc · Executive Compensation

$0.30 +0.01 (+4.16%) At close · Nov 4

Market Cap

$46.47M

159.69M

Volume · Nov 4 526.05K Avg daily vol (3M) 3.9M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Denise Scots-Knight	Chief Executive Officer	$565,107	$254,298	$285,358	$1,043,403	—	$71,157	$2,219,323
Charles Sermon	General Counsel	$415,651	$162,104	$99,540	$362,923	—	$48,031	$1,088,249
Christine Fox	Chief Financial Officer	$378,120	$151,248	$91,043	$340,240	—	$40,400	$1,001,051

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Denise Scots-Knight	Chief Executive Officer	$506,809	$304,085	—	$1,358,134	—	$68,219	$2,237,247
Charles Sermon	General Counsel	$372,772	$186,386	—	$339,533	—	$51,198	$949,889
Christine Fox	Chief Financial Officer	$332,833	$166,416	—	$271,627	—	$40,063	$810,939

Leadership

Dr. Denise Scots-Knight CEO, Board Member
Michael S. Wyzga Chairman
Christine Fox CFO
Charles Sermon General Counsel
Dr. Anders Ekblom Board Member
Dr. Annalisa Jenkins Board Member
Dr. Daniel Shames Board Member
Dr. Deepika R. Pakianathan Board Member
Dr. Jeremy Bender Board Member
Dr. Pierre Jacquet Board Member
Justin Roberts Board Member
Marc Yoskowitz Board Member

Key facts CIK 1719714 CUSIP 589492107 13F (30d) 9 filings 9 filers Visit website Investor relations